NEW YORK, May 19, 2016 /PRNewswire/ --
There is no saying when exactly the Biotech space will fully
recover given the relentless pressures in pricing and lack in
consumer confidence. One thing is for sure in the investors circle
though - numerous opportunities are up for grabs but this industry
requires due-diligence. Ahead of today's session,
ActiveWallSt.com's presents four names in this sector: Portola
Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc.
(NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and
Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your
complimentary alerts on these stocks by signing up today at:
http://www.activewallst.com/
Below are these stocks' performances at the close on
Wednesday, May 18, 2016:
Portola Pharmaceuticals Inc.'s shares surged 5.37% and finished
the trading session at $25.91. A
total volume of 763,111 shares was traded. In the last one month,
the stock has advanced 7.11%. The Company's shares are trading
above their 50-day moving average 5.49%. Moreover, shares of
Portola Pharmaceuticals have a Relative Strength Index (RSI) of
56.20. Sign up and get the alert on PTLA at:
http://www.activewallst.com/
On Wednesday, shares in Vitae Pharmaceuticals Inc. recorded a
trading volume of 202,910 shares, and ended the session 3.92%
higher at $7.69. The stock has gained
1.99% in the last one month. The Company's shares are trading
14.24% above their 50-day moving average. Furthermore, Vitae
Pharmaceuticals' stock has an RSI of 57.64. The complimentary alert
on VTAE can be activated at:
http://www.activewallst.com/
Shares in Anthera Pharmaceuticals Inc. closed the day at
$3.36, which was a correction of
1.18%. The stock recorded a trading volume of 410,156 shares. The
Company's shares have surged 15.86% in the previous three months
and are trading 9.67% below their 50-day moving average.
Additionally, Anthera Pharmaceuticals' stock has an RSI of 45.92.
Register for free on ActiveWallSt.com and access the latest
strategies on ANTH at:
http://www.activewallst.com/
At the closing bell yesterday, shares in Intra-Cellular
Therapies Inc. ended 2.61% higher at $34.59, and with a total volume of 355,491 shares
traded. The stock has advanced 15.88% in the previous three months.
The Company's shares are trading above their 50-day moving average
by 9.73%. Furthermore, shares of Intra-Cellular Therapies have an
RSI of 56.15. The complete trade setup on ITCI is available for
free at:
http://www.activewallst.com/
--
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. AWS has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
AWS has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by AWS. AWS is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. AWS, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, AWS, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither AWS nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.activewallst.com
CONTACT
For any questions, inquiries, or comments reach out to us directly
at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA